Stocks | |||||
The table gives an overview of all stocks, alphabetically sorted. | |||||
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z |
Name | Symbol | Analysis date | Close | +/- % |
Accelerate Diagnostics | AXDX | Nov 22, 2024 | 1.64 | -1.80 |
Accenture A | ACN | Nov 22, 2024 | 358.66 | -0.66 |
Acco Brands | ACCO | Nov 22, 2024 | 5.82 | +2.65 |
Accolade | ACCD | Nov 22, 2024 | 3.70 | -0.27 |
Accuray | ARAY | Nov 22, 2024 | 1.93 | +2.12 |
Acelyrin | SLRN | Nov 22, 2024 | 4.70 | +8.55 |
Achieve Life Sciences | ACHV | Nov 22, 2024 | 4.29 | -0.92 |
Achilles Therapeutics ADR | ACHL | Nov 22, 2024 | 1.06 | -0.93 |
ACI Worldwide | ACIW | Nov 22, 2024 | 58.64 | +5.24 |
Aclarion | ACON | Nov 22, 2024 | 0.18 | -1.73 |
Aclaris Therapeutics | ACRS | Nov 22, 2024 | 3.80 | -12.04 |
ACM Research A | ACMR | Nov 22, 2024 | 18.79 | -2.03 |
Acme United | ACU | Nov 22, 2024 | 42.96 | +2.85 |
ACNB | ACNB | Nov 22, 2024 | 47.96 | +0.71 |
ACRES Commercial Realty | ACR | Nov 22, 2024 | 16.75 | +0.06 |
ACRES Commercial Realty C Pref | ACR-C | Nov 22, 2024 | 25.08 | -0.18 |
ACRES Commercial Realty D Pref | ACR-D | Nov 22, 2024 | 22.80 | -0.57 |
Acrivon Therapeutics | ACRV | Nov 22, 2024 | 6.55 | +1.71 |
Actelis Networks | ASNS | Nov 22, 2024 | 1.21 | +1.68 |
Actinium Pharmaceuticals | ATNM | Nov 22, 2024 | 1.45 | -1.36 |
Active Bear ETF | HDGE | Nov 22, 2024 | 17.04 | -1.18 |
Active U.S. Real Estate Powershares | PSR | Nov 22, 2024 | 97.34 | +0.62 |
Actuate Therapeutics | ACTU | Nov 22, 2024 | 8.98 | -0.22 |
Acuity Brands | AYI | Nov 22, 2024 | 326.24 | +1.82 |
Acumen Pharmaceuticals | ABOS | Nov 22, 2024 | 2.37 | +2.60 |
Acurx Pharmaceuticals | ACXP | Nov 22, 2024 | 1.35 | +3.85 |
Acushnet | GOLF | Nov 22, 2024 | 71.96 | +0.80 |
ACV Auctions A | ACVA | Nov 22, 2024 | 21.97 | +2.00 |
ACWI Ex-US Index MSCI Ishares | ACWX | Nov 22, 2024 | 53.81 | +0.20 |
ACWI Index MSCI Ishares | ACWI | Nov 22, 2024 | 120.44 | +0.36 |
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.
Investtech guarantees neither the entirety nor accuracy of the analyses. Any consequent exposure related to the advice / signals which emerge in the analyses is completely and entirely at the investors own expense and risk. Investtech is not responsible for any loss, either directly or indirectly, which arises as a result of the use of Investtechs analyses. Details of any arising conflicts of interest will always appear in the investment recommendations. Further information about Investtechs analyses can be found here disclaimer.
The content provided by Investtech.com is NOT SEC or FSA regulated and is therefore not intended for US or UK consumers.